COMPANY NEWS

November 13, 2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 12, 2024

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

November 8, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

November 7, 2024

Travere Therapeutics Announces Proposed Public Offering of Common Stock

November 4, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences

October 31, 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results

October 26, 2024

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

October 21, 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results

October 17, 2024

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

October 9, 2024

Jula Inrig Recognized in Endpoints News’ Women in Biopharma R&D, 2024

October 8, 2024

William Rote Recognized in PharmaVoice 100 Industry Leaders Reshaping the Pharma World

September 19, 2024

Travere CEO Eric Dube Named to Fortune’s LGBTQ+ Leaders List